New developments of aminobisphosphonates: The double face of Janus

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Santini, D ^a   Galluzzo, S ^a   Vincenzi, B ^a   Schiavon, G ^a   Fratto, E ^a   Pantano, F ^a   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Bisphosphonates; Bone loss; Bone metastases; Survival; Zoledronic acid

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOTOXIC AGENT; IBANDRONIC ACID; LETROZOLE; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BONE CANCER; BONE DEFECT; BONE DENSITY; BONE METASTASIS; BONE MINERALIZATION; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK REDUCTION; SIDE EFFECT; SOLID TUMOR; SURVIVAL RATE; TREATMENT DURATION; ANIMAL; BONE TUMOR; METASTASIS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; HUMANS; IMIDAZOLES;

EID: 35748954666     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm249     Document Type: Conference Paper

References (45)

1. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-34.
2. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporosis Int 1999; 9 (Suppl 2): S66-S80.
3. Benford HL, Frith JC, Auriola S et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999; 56: 131-140.
4. Luckman SP, Coxon FP, Ebetino FH et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998; 13: 1668-1678.
5. Luckman SP, Hughes DE, Coxon FP et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-589.
6. Russell RG, Rogers MJ, Frith JC et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999; 14 (Suppl 2): 53-65.
7. Oliff A. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer. Biochim Biophys Acta 1999; 1423: C19-C30.
8. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241-269.
9. Lehenkari PP, Kellinsalmi M, Napankangas JP et al. Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002; 61: 1255-1262.
10. Selander KS, Monkkonen J, Karhukorpi EK et al. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996; 50: 1127-1138.
11. Santini D, Fratto ME, Vincenzi B et al. Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther 2006; 6: 1333-1348.
12. Hasmin M, Bieler G, Ruegg G. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signalling pathways. J Thromb Haemost 2007; 5: 166-173.
13. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001; 61: 4418-4424.
14. Senaratne SG, Pirianov G, Mansi JL et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459-1468.
15. Shipman CM, Rogers MJ, Apperley JF et al. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity, Br J Haematol 1997; 98: 665-672.
16. Shipman CM, Croucher PI, Russell RG et al. The bisphosphonate incadronate [YM175] causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 5294-5297.
17. Takahashi R, Shimazaki C, Inaba T et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 2001; 25: 77-83.
18. Tassone P, Tagliaferri P, Viscomi C et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003; 88: 1971-1978.
19. Benford HL, McGowan NWA, Helfrich MH et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001; 28: 465-473.
20. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211-2221.
21. Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002; 29: 33-42.
22. Croucher PI, De Hendrik R, Perry MJ et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18: 482-492.
23. Kunzmann V, Bauer E, Feurle J et al. Stimulation of gamma/delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384-392.
24. Dieli F, Gebbia N, Poccia F et al. Induction of gamma/delta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102: 2310-2311.
25. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002; 86: 1479-1486erratum in Br J Cancer 2002; 87: 1340.
26. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949-2954.
27. Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 3890-3894.
28. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999 83: 263-269.
29. van der Pluijm G, Vloedgraven H, van Beek E et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698-705.
30. Bezzi M, Hasmim M, Bieler G et al. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003; 278: 43603-43614.
31. Santini D, Vincenzi B, Avvisati G et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8: 1080-1084.
32. Santini D, Vincenzi B, Dicuonzo G et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9: 2893-2897.
33. Vincenzi B, Santini D, Dicuonzo G et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005; 25: 144-1451.
34. Gouin F, Gory B, Redini F, Heymann D. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 2006; 119: 980-984.
35. Yaccoby S, Pearse RN, Johnson CL et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116: 278-290.
36. Hiraga T, Williams PJ, Ueda A et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10: 4559-4567.
37. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 2005; 16: 845-854.
38. Algur E, Macklis RM, Hafeli UO. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines, Int J Radiat Oncol Biol Phys 2005; 61: 535-542.
39. Caraglia M, Giuberti G, Marra M et al. Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front Biosci 2005; 10: 2566-2575.
40. Kimura S, Kuroda J, Segawa H et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004; 79: 37-43.
41. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergo in adjuvant breast cancer therapy: A Z-FAST update. Semin. Oncol 2006; 33: S13-S17.
42. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZO-FAST program. Breast 2006; 15: S30-S340.
43. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25: 829-836.
44. Lipton A. Toward new horizons: The future of bisphosphonate therapy. Oncologist 2004; S4: 38-47.
45. Mystakidou K, Katsouda E, Parpa E et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22: 195-201.